Table 6.

Comparison of fluorodeoxyglucose-positron emission tomography response criteria[78,80,81,84]

	EORTC PET, 1999	PERCIST, 2009	iPERCIST, 2019
CMR	Complete Resolution of FDG uptake1	Complete Resolution of FDG uptake	Complete Resolution of FDG uptake
PMR	15-25% decrease of SUV after one cycle or > 25% decrease after more than one treatment cycle	≥ 30% decrease in the target tumor SULpeak	≥ 30% decrease in the target tumor SULpeak
SMD	Increase of SUV by < 25% or decrease of SUV by < 15%	Neither CR, PR nor PD	Neither CR, PR nor PD
PMD	Increase of SUV by > 25% or Increase of the longest diameter by 20% or new FDG avid lesion(s)	≥ 30% increase in SULpeak or advent of new FDG avid lesions	≥ 30% increase in SULpeak or advent of new FDG avid lesions (UPMD); Need to be confirmed by a second PET at 4-8 wk later (CPMD)

¹Indistinguishable from surrounding background. CMR: Complete metabolic response; PMR: Partial metabolic response; SMD: Stable metabolic disease; PMD: Progressive metabolic disease; UPMD: Unconfirmed progressive metabolic disease; CPMD: Confirmed progressive metabolic disease; PET: Positron emission tomography; SUV: Standardized uptake value; FDG: Fluorodeoxyglucose; SUL: Standardized uptake value, normalized to the lean body mass; EORTC: European Organization for Research in the Treatment of Cancer; PERCIST: Positron emission tomography response criteria in solid tumors; iPERCIST: İmmune positron emission tomography Response Criteria.